Harmony Biosciences is trading at $35.95, down 6.16%, amid a broad selloff; available reporting surfaced no clear company-specific catalyst for the October 22 decline.
- Major indexes were lower, with AI-spending concerns and rising oil prices weighing on sentiment.
- Reuters reported Tesla and Meta results did little to ease AI-related concerns, while recovering oil prices added to market unease.
- The CEO transition and patent-risk discussion are background, not established causes of this move.